Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases

A method for the treatment of fibrosis, or a fibrosis-related disease, whereby a therapeutically effective amount of a compound of Formula I

• wherein
• n=0, 1 or 2;
• R1 and R2 are each independently selected from hydrogen;
• saturated or unsaturated, branched or unbranched C1-10 alkyl or C3-12 cycloalkyl;
• and substituted or non-substituted phenyl or benzyl;
• R3 is hydrogen;
• or saturated or unsaturated, branched or unbranched C1-10 alkyl or C3-12 cycloalkyl;
• R4 is substituted or non-substituted C6-C10 aryl or C5-C9 heteroaryl wherein the heteroatoms independently are selected from N, O and S;
• or substituted or non-substituted mono- or bicyclic C3-12 cycloalkyl or C5-C9 heterocyclyl wherein the heteroatoms are independently selected from N, O and S;
• or a pharmaceutically acceptable salt thereof;
• is administered to a patient in need of such treatment.

A pharmaceutical combination, comprising

• (i) a compound of Formula I
• wherein
• n=0, 1 or 2;
• R1 and R2 are each independently selected from hydrogen;
• saturated or unsaturated, branched or unbranched C1-10 alkyl or C3-12 cycloalkyl;
• and substituted or non-substituted phenyl or benzyl;
• R3 is hydrogen;
• or saturated or unsaturated, branched or unbranched C1-10 alkyl or C3-12 cycloalkyl;
• R4 is substituted or non-substituted C6-C10 aryl or C5-C9 heteroaryl wherein the heteroatoms independently are selected from N, O and S;
• or substituted or non-substituted mono- or bicyclic C3-12 cycloalkyl or C5-C9 heterocyclyl wherein the heteroatoms are independently selected from N, O and S;
• or a pharmaceutically acceptable salt thereof;
• and
• (ii) a drug that suppresses the immune system or which has other beneficial effects targeting processes that precede fibrosis;
• for simultaneous, separate or sequential administration.